AIHealthcare Analytics

AI in Immunotherapy Optimization

AI technologies have impacted cancer immunotherapy across response prediction, patient stratification for immune checkpoint blockade, and identification of potent T-cells for cellular therapies. Generative AI and foundation models have expanded applications to treatment plan generation and adverse event prediction. Emerging agentic AI and model context protocol (MCP) technologies are expected to further improve immunotherapy development and delivery. Key challenges include data quality control, patient safety, and ethical dilemmas.

Breast Cancer AI Applications

A scoping review of 54 studies (2016–2024) found machine learning as the predominant technology (81%) in post-diagnosis breast cancer care, followed by generative AI (7%), conversational agents (6%), NLP (4%), and data mining (2%). Follow-up and surveillance was the most represented care stage (48%), driven primarily by recurrence prediction. Most applications were provider-focused (83%); no studies addressed palliative care. Evidence was predominantly retrospective (70%) and concentrated in high-income countries (74%).

Treatment Recommendation Quality

A retrospective study of 100 advanced/recurrent breast cancer patients found ChatGPT scored higher than six board-certified breast cancer specialists across all five evaluation criteria including comprehensiveness of literature selection, accuracy of evidence interpretation, clinical appropriateness of treatment options, accuracy of adverse event information, and time to generate recommendations (mean total: 93.7 vs. 44.1). However, these findings reflect structured evidence synthesis within predefined criteria rather than holistic clinical judgment.

Medical Digital Twins

Medical digital twins enhanced with generative modeling enable simulation of individual patient biological processes for cancer therapy. By integrating genetic profiles, medical imaging, and clinical data, these models support treatment scenario testing to predict cellular responses, efficacy, and toxicity before clinical application. Integration of generative modeling with digital twins is expected to enhance treatment success rates, though clinical validation remains in early stages.